目的 探討益脈康膠囊聯(lián)合康柏西普眼用注射液治療視網(wǎng)膜靜脈阻塞的臨床療效。方法 選取2019年8月—2020年12月在中國(guó)人民武裝警察部隊(duì)河南省總隊(duì)醫(yī)院眼科就診的106例視網(wǎng)膜靜脈阻塞患者作為研究對(duì)象，所有患者按隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各53例。對(duì)照組采用無(wú)菌針管將康柏西普眼用注射液注入角膜緣后4 mm睫狀體平坦部位，0.05 mL/次，1次/月，共治療3次。治療組在對(duì)照組基礎(chǔ)上口服益脈康膠囊，0.6 g/次，3次/d。兩組在治療3個(gè)月統(tǒng)計(jì)療效。觀察兩組的臨床療效，評(píng)估兩組患者治療前后黃斑中心凹厚度、最佳矯正視力值（BCVA）。檢測(cè)患者的血清白細(xì)胞介素-6（IL-6）、巨噬細(xì)胞炎性蛋白-1（MIP-1）、超敏C-反應(yīng)蛋白（hs-CRP）水平。結(jié)果 治療后，治療組患者的總有效率為94.34%，對(duì)照組的總有效率為81.13%，組間有明顯差異（P<0.05）。治療后，兩組的黃斑中心凹厚度顯著降低，BCVA明顯升高（P<0.05）；治療組的黃斑中心凹厚度比對(duì)照組低（P<0.05），BCVA比對(duì)照組高。治療后，兩組的IL-6、MIP-1、hs-CRP水平顯著降低（P<0.05），治療組IL-6、MIP-1、hs-CRP水平降低比對(duì)照組明顯（P<0.05）。結(jié)論 益脈康膠囊聯(lián)合康柏西普眼用注射液治療視網(wǎng)膜靜脈阻塞具有較好的臨床療效，可提高視力，減輕炎癥反應(yīng)，不增加不良反應(yīng)。

Objective To investigate the clinical efficacy of Yimaikang Capsules combined with Conbercept Ophthalmic Injection in treatment of retinal vein occlusion. Methods Patients (106 cases) with retinal vein occlusion in Henan Provincial Corps Hospital of Chinese People's Armed Police Force from August 2019 to December 2020 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were injection administered with Conbercept Ophthalmic Injection at the flat part of the ciliary body 4 mm behind the limbus of cornea, 0.05 mL/time, once monthly. Patients in the treatment group were po administered with Yimaikang Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the macular fovea thickness and BCVA levels of the two groups before and after treatment were evaluated. The serum levels of IL-6, MIP-1, and hs-CRP were detected. Results After treatment, the total effective rate of the treatment group was 94.34%, the total effective rate of the control group was 81.13%, and there was a significant difference between the two groups (P < 0.05). After treatment, the thickness of macular fovea in two groups were significantly decreased, but the BCVA in two groups were significantly increased (P < 0.05). The thickness of macular fovea in the treatment group was lower than that in the control group, but the BCVA in the treatment group was higher than that in the control group (P < 0.05). After treatment, the levels of IL-6, MIP-1, and hs-CRP in two groups were significantly decreased (P < 0.05). The levels of IL-6, MIP-1, and hs-CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Yimaikang Capsules combined with Conbercept Ophthalmic Injection has clinical curative effect in treatment of retinal vein occlusion, can improve vision, reduce inflammatory reaction, without increasing the risk of adverse reactions.

R971;R988.1

開(kāi)封市科技發(fā)展計(jì)劃項(xiàng)目（200302741）